Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVRX NASDAQ:GUTS NASDAQ:MBOT NYSE:NSPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVRXCVRx$4.74$5.38$4.37▼$11.30$125.80M0.81252,784 shs197,354 shsGUTSFractyl Health$0.77$0.80$0.38▼$2.45$122.64M2.291.79 million shs1.77 million shsMBOTMicrobot Medical$1.71$1.84$1.60▼$4.67$114.86M1.04649,622 shs369,397 shsNSPRInspireMD$0.68$0.79$0.63▼$2.93$32.02M0.78162,445 shs15,509 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVRXCVRx0.00%-3.46%-19.11%-38.04%-43.17%GUTSFractyl Health0.00%-4.57%+4.04%+18.36%-59.74%MBOTMicrobot Medical0.00%-2.29%-3.66%-21.20%-42.42%NSPRInspireMD0.00%-2.57%-5.06%-43.50%-71.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVRXCVRx$4.74$5.38$4.37▼$11.30$125.80M0.81252,784 shs197,354 shsGUTSFractyl Health$0.77$0.80$0.38▼$2.45$122.64M2.291.79 million shs1.77 million shsMBOTMicrobot Medical$1.71$1.84$1.60▼$4.67$114.86M1.04649,622 shs369,397 shsNSPRInspireMD$0.68$0.79$0.63▼$2.93$32.02M0.78162,445 shs15,509 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVRXCVRx0.00%-3.46%-19.11%-38.04%-43.17%GUTSFractyl Health0.00%-4.57%+4.04%+18.36%-59.74%MBOTMicrobot Medical0.00%-2.29%-3.66%-21.20%-42.42%NSPRInspireMD0.00%-2.57%-5.06%-43.50%-71.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVRXCVRx 2.67Moderate Buy$11.50142.62% UpsideGUTSFractyl Health 2.50Moderate Buy$5.12562.35% UpsideMBOTMicrobot Medical 3.00Buy$6.63287.43% UpsideNSPRInspireMD 3.00Buy$4.50558.28% UpsideCurrent Analyst Ratings BreakdownLatest NSPR, CVRX, GUTS, and MBOT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2026MBOTMicrobot Medical Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/14/2026MBOTMicrobot Medical HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/8/2026MBOTMicrobot Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/6/2026GUTSFractyl Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/1/2026GUTSFractyl Health Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.007/1/2026GUTSFractyl Health Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.006/4/2026GUTSFractyl Health HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.006/3/2026MBOTMicrobot Medical Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.005/12/2026GUTSFractyl Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/6/2026CVRXCVRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/5/2026NSPRInspireMD Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$4.00 ➝ $3.00(Data available from 7/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVRXCVRx$56.65M2.22N/AN/A$1.50 per share3.16GUTSFractyl Health$90K1,362.63N/AN/A$0.07 per share11.04MBOTMicrobot MedicalN/AN/AN/AN/A$1.15 per shareN/ANSPRInspireMD$10.85M2.95N/AN/A$1.83 per share0.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVRXCVRx-$53.31M-$2.02N/AN/AN/A-89.14%-120.76%-48.38%8/6/2026 (Estimated)GUTSFractyl Health-$140.95M-$1.29N/AN/AN/AN/A-4,053.15%-96.41%8/11/2026 (Estimated)MBOTMicrobot Medical-$13.14M-$0.26N/AN/AN/AN/A-21.84%-20.71%8/11/2026 (Estimated)NSPRInspireMD-$19.92M-$0.73N/AN/AN/A-413.96%-69.42%-57.68%N/ALatest NSPR, CVRX, GUTS, and MBOT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026GUTSFractyl Health-$0.15N/AN/AN/AN/AN/A8/11/2026Q2 2026MBOTMicrobot Medical-$0.08N/AN/AN/A$0.33 millionN/A8/6/2026Q2 2026CVRXCVRx-$0.52N/AN/AN/A$15.55 millionN/A5/13/2026Q1 2026MBOTMicrobot Medical-$0.08-$0.05+$0.03-$0.05$0.30 million$0.11 million5/12/2026Q1 2026GUTSFractyl Health-$0.17$0.06+$0.23$0.06N/AN/A5/11/2026Q1 2026CVRXCVRx-$0.51-$0.50+$0.01-$0.50$14.49 million$14.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCVRXCVRxN/AN/AN/AN/AN/AGUTSFractyl HealthN/AN/AN/AN/AN/AMBOTMicrobot MedicalN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVRXCVRx2.0110.208.89GUTSFractyl Health1.414.284.28MBOTMicrobot Medical0.0122.5921.93NSPRInspireMDN/A6.396.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVRXCVRx75.27%GUTSFractyl HealthN/AMBOTMicrobot Medical16.30%NSPRInspireMD44.78%Insider OwnershipCompanyInsider OwnershipCVRXCVRx18.90%GUTSFractyl Health8.52%MBOTMicrobot Medical4.74%NSPRInspireMD34.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVRXCVRx16026.54 million21.52 millionOptionableGUTSFractyl Health102158.65 million145.13 millionN/AMBOTMicrobot Medical2067.17 million63.98 millionOptionableNSPRInspireMD5046.84 million18.33 millionOptionableNSPR, CVRX, GUTS, and MBOT HeadlinesRecent News About These CompaniesInspireMD Receives Nasdaq Notice on Bid Price ComplianceJuly 23, 2026 | tipranks.comLake Street Sticks to Its Buy Rating for InspireMD (NSPR)June 18, 2026 | theglobeandmail.comInspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCARJune 16, 2026 | zacks.comInspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 12, 2026 | globenewswire.comInspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR ProceduresJune 11, 2026 | globenewswire.comInspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard(TM) Neuroprotection SystemJune 10, 2026 | stockhouse.comInspireMD Initiates CGUARDIANS III Study for SwitchGuard Neuro Protection System in TCAR ProceduresJune 8, 2026 | quiverquant.comQInspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR ProceduresJune 8, 2026 | globenewswire.comInspireMD NSPR Q1 2026 Earnings TranscriptJune 1, 2026 | finance.yahoo.comInsider Buying: InspireMD (NYSE:NSPR) Director Acquires 20,000 Shares of StockMay 30, 2026 | insidertrades.comShane Thomas Gleason Sells 3,858 Shares of InspireMD (NYSE:NSPR) StockMay 22, 2026 | insidertrades.comInspireMD (NSPR) Stock Forecast & Price TargetMay 21, 2026 | investing.comInspireMD (NASDAQ:NSPR) Stock, Earnings Estimates, EPS, And RevenueMay 15, 2026 | benzinga.comInspireMD (NSPR) price target decreased by 13.33% to 4.42May 14, 2026 | msn.comMarvin Slosman Buys 21,000 Shares of InspireMD (NYSE:NSPR) StockMay 14, 2026 | insidertrades.comInspireMD, Inc. (NSPR) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks TranscriptMay 13, 2026 | seekingalpha.comInspireMD (NYSE:NSPR) Director Buys $11,900.00 in StockMay 13, 2026 | insidertrades.comScott Ward Buys 15,995 Shares of InspireMD (NYSE:NSPR) StockMay 9, 2026 | insidertrades.comInspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare ConferenceMay 6, 2026 | globenewswire.comInspireMD Inc.: InspireMD Reports First Quarter 2026 Financial ResultsMay 5, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNSPR, CVRX, GUTS, and MBOT Company DescriptionsCVRx NASDAQ:CVRX$4.74 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$4.72 -0.02 (-0.32%) As of 07/24/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Fractyl Health NASDAQ:GUTS$0.77 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.77 0.00 (-0.13%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.Microbot Medical NASDAQ:MBOT$1.71 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.73 +0.02 (+1.23%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.InspireMD NYSE:NSPR$0.68 0.00 (0.00%) Closing price 07/24/2026 03:50 PM EasternExtended Trading$0.68 0.00 (-0.53%) As of 07/24/2026 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
